New Data Support Osimertinib as a Backbone Treatment for EGFRm Advanced NSCLC

New COMPEL trial data suggest that continued EGFR inhibition with osimertinib plus chemotherapy prolongs both PFS and OS in EGFRm advanced NSCLC following progression on first-line therapy.